GSK reports positive Mo-Rez trial data in platinum-resistant ovarian cancer
Bitget2026/10/23 22:08- GSK presented positive results for Mo-Rez in platinum-resistant ovarian cancer from the phase I BEHOLD-1 trial.
- Common side effects were gastrointestinal and hematological, consistent with the treatment class; treatment-related adverse events prompted dose interruptions or reductions.
- Five pivotal phase III trials are underway across ovarian and endometrial cancers.
- Endometrial cancer patients receiving the selected phase III dose remain under follow-up, with results expected to be presented in the future.
Disclaimer: The content of this article solely reflects the author's opinion and does not represent the platform in any capacity. This article is not intended to serve as a reference for making investment decisions.
You may also like
Circle issues 500 million USDC on the Solana network

Cardano vs Solana: Analysts and ADA Holders Clash Over Adoption

Ming-Chi Kuo: Google reduces next year's Broadcom-designed TPU shipments by 20% and plans to increase MediaTek's share
Renowned Apple and supply chain analyst Ming-Chi Kuo pointed out that Google has reduced the 2027 shipment volume of the TPU 8i series, designed by Broadcom, by about 1 million units, while planning to increase its procurement of the TPU 8t, designed by MediaTek. This move reflects that, limited by power and supply chain constraints, Google is prioritizing its computing resources towards the development of cutting-edge models.

